Citadel Advisors’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.6M | Buy |
259,401
+203,564
| +365% | +$1.12M | ﹤0.01% | 7053 |
|
|
2026
Q1 | $250K | Sell |
55,837
-71,781
| -56% | -$359K | ﹤0.01% | 10910 |
|
|
2025
Q4 | $673K | Sell |
127,618
-145,828
| -53% | -$734K | ﹤0.01% | 8291 |
|
|
2025
Q3 | $1.44M | Buy |
+273,446
| New | +$1.73M | ﹤0.01% | 6744 |
|
|
2025
Q2 | – | Sell |
-32,044
| Closed | -$182K | – | 12306 |
|
|
2025
Q1 | $153K | Buy |
32,044
+30,762
| +2,400% | +$167K | ﹤0.01% | 10850 |
|
|
2024
Q4 | $7.14K | Buy |
1,282
+573
| +81% | +$3.53K | ﹤0.01% | 13751 |
|
|
2024
Q3 | $4.48K | Sell |
709
-3,521
| -83% | -$18.4K | ﹤0.01% | 13562 |
|
|
2024
Q2 | $17.9K | Buy |
4,230
+4,226
| +105,650% | +$21.6K | ﹤0.01% | 12732 |
|
|
2024
Q1 | $29 | Sell |
4
-91,116
| -100% | -$577K | ﹤0.01% | 14447 |
|
|
2023
Q4 | $457K | Buy |
+91,120
| New | +$401K | ﹤0.01% | 8303 |
|
|
2022
Q2 | – | Sell |
-3,759
| Closed | -$29K | – | 12754 |
|
|
2022
Q1 | $29K | Sell |
3,759
-9,549
| -72% | -$65.6K | ﹤0.01% | 13117 |
|
|
2021
Q4 | $112K | Buy |
+13,308
| New | +$244K | ﹤0.01% | 12601 |
|
|
2021
Q3 | – | Sell |
-2,143
| Closed | -$83K | – | 13708 |
|
|
2021
Q2 | $83K | Sell |
2,143
-4,821
| -69% | -$197K | ﹤0.01% | 13049 |
|
|
2021
Q1 | $327K | Sell |
6,964
-107,874
| -94% | -$5.94M | ﹤0.01% | 10637 |
|
|
2020
Q4 | $4.51M | Buy |
114,838
+73,844
| +180% | +$2.52M | ﹤0.01% | 3861 |
|
|
2020
Q3 | $1.04M | Sell |
40,994
-17,466
| -30% | -$1.1M | ﹤0.01% | 5951 |
|
|
2020
Q2 | $4.26M | Buy |
58,460
+3,846
| +7% | +$266K | ﹤0.01% | 3310 |
|
|
2020
Q1 | $2.87M | Buy |
54,614
+38,603
| +241% | +$2.58M | ﹤0.01% | 3530 |
|
|
2019
Q4 | $1.31M | Buy |
16,011
+1,998
| +14% | +$141K | ﹤0.01% | 5105 |
|
|
2019
Q3 | $792K | Sell |
14,013
-6,848
| -33% | -$513K | ﹤0.01% | 5990 |
|
|
2019
Q2 | $2.49M | Buy |
+20,861
| New | +$3.5M | ﹤0.01% | 4145 |
|
|
2018
Q4 | – | Sell |
-1,596
| Closed | -$348K | – | 9005 |
|
|
2018
Q3 | $511K | Buy |
1,596
+257
| +19% | +$91.2K | ﹤0.01% | 6653 |
|
|
2018
Q2 | $536K | Sell |
1,339
-63,897
| -98% | -$27.9M | ﹤0.01% | 6253 |
|
|
2018
Q1 | $23.4M | Buy |
65,236
+64,733
| +12,869% | +$24.1M | 0.01% | 1006 |
|
|
2017
Q4 | $199K | Sell |
503
-56,950
| -99% | -$23.6M | ﹤0.01% | 7122 |
|
|
2017
Q3 | $24.5M | Buy |
+57,453
| New | +$15.4M | 0.02% | 942 |
|
|
2017
Q1 | – | Sell |
-654
| Closed | -$79K | – | 7364 |
|
|
2016
Q4 | $79K | Buy |
+654
| New | +$102K | ﹤0.01% | 6755 |
|
Other funds holding ABEO
NCM
CCC
ACM
OIA
AIC
KCM
Citadel Advisors's ABEO Position: Q2 2026 in Review
Citadel Advisors increased its Abeona Therapeutics (ABEO) stake by 365% in Q2 2026, buying an estimated $1.12M and bringing the position to 259,401 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #7053.
Citadel Advisors first reported a position in ABEO in Q4 2016 and has held it in 27 quarters since. The position peaked at $24.5M in Q3 2017. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- Citadel Advisors held 259,401 shares of Abeona Therapeutics worth $1.6M as of Q2 2026.
- Citadel Advisors bought 203,564 Abeona Therapeutics shares in Q2 2026, an estimated $1.12M.
- Abeona Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7053 holding.
- Citadel Advisors first reported a position in Abeona Therapeutics in Q4 2016 and has held it in 27 quarters since.
- Citadel Advisors's Abeona Therapeutics position peaked at $24.5M in Q3 2017.
- 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.